- Review
Background/Objectives: Bacterial vaginosis (BV) is the leading cause of vaginal dysbiosis and remains a public health concern due to its high prevalence, recurrence, and association with adverse reproductive and infectious outcomes. Advances in next-generation sequencing (NGS) and microbiome characterization have redefined BV by revealing microbial composition profiles known as Community State Types (CSTs). Once regarded primarily as a polymicrobial infection, BV is now recognized as a multifactorial ecological disorder marked by microbiome instability, Lactobacillus depletion, anaerobic overgrowth, host–microbe interactions, and clinical heterogeneity. Methods: This narrative review critically analyzes recent evidence on vaginal microbial ecology, the transition from eubiosis to dysbiosis, and the mechanisms underlying BV development, persistence, and recurrence. This review focuses on interactions between BV-associated microorganisms and Trichomonas vaginalis, including microbial persistence, immune modulation, and susceptibility to Sexually Transmitted Infections (STIs). Results: BV involves ecological, metabolic, and immunological changes, including polymicrobial biofilm formation, alterations in the mucosal metabolome, and impaired resistance to colonization by other microorganisms. These changes may facilitate microbial persistence, recurrence, and T. vaginalis persistence. This is reflected in the association between BV and an increased risk of STIs, although the cause has not yet been fully established. Microbial resistance and recurrence underscore the need for new interventions, while probiotics, live biotherapeutic products, vaginal microbiota transplantation (VMT), targeted therapies, and vaccines have shown promising results. Conclusions: Integrating microbiological, immunological, and clinical evidence, this review provides a framework for BV pathophysiology and its association with T. vaginalis, supporting personalized therapeutic and prophylactic strategies.
19 November 2026



